Cited by 6,902Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismBlood Pressure and Hypertension Studies

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Open access
Grundy, Scott M., Cleeman, James I., Merz, C. Noel Bairey, Brewer, H. Bryan, Clark, Luther T., Hunninghake, Donald B., Pasternak, Richard C., Smith, Sidney C. +1 more·2004·Circulation

Abstract

The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000133317.49796.0e

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Using combined fibrate-statin therapy in type 2 diabetes patients with substantial dyslipidemia aligns with current guidelines for persistent hypertriglyceridemia and low HDL cholesterol despite statin therapy.

    “The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”

    From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]

    The “Other Lipid Targets” section says fibrates may have an adjunctive role for high triglycerides and low HDL-C, especially with statins, and notes particular relevance to patients with diabetes. The paper presents this as an option, not a firm guideline recommendation, and does not specify that the abnormalities must persist despite statin therapy. Page numbers were not provided for these passages. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, which were set on the basis of a patient's risk of cardiovascular events.

    “According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
  • Statins have been shown to reduce CV events in a wide variety of patient populations.

    “Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
  • Statins are currently the most effective agents available for managing dyslipidemia.

    “Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
  • Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.

    “Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 54 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Dean BB, Borenstein JE, Henning JM, Knight K, Bairey Merz CN. Can change in HDL-cholesterol reduce cardiovascular risk? Am Heart J. 2004;147:966 -976.
  2. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92: 152-160.
  3. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587.

Cited by

Sorted by citations

Authors
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
Affiliations
American College of Cardiology (US)
Venue
Circulation
Published
2004-07-13
Volume
110
Issue
2
Pages
227-239
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2106343349
Cited by
6,902
References
54
Citations by year
2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
FWCI
539.21
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Funders
  • American Heart Association
  • American College of Cardiology Foundation
  • National Heart, Lung, and Blood Institute
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
MeSH terms
Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review